Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com
The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.
In an unprecedented age of health care burnout, hospital administrators may need to think outside of the box to find ways to engage and support employees.
Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.
In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.
At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.
Patients with hormone-sensitive prostate cancer who received darolutamide in combination with docetaxel experienced superior overall survival and time-to-pain progression benefit.
The FDA has approved the first targeted therapy for patients with HER2-low metastatic breast cancer.
Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.
Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.
Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.
Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.
Beth Sandy, MSN, CRNP, discusses some of the challenges that may be associated with molecular testing, and how oncology nurses can help play a role in ensuring that the reports are received.
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.
Gretchen McNally, PhD, ANP-BC, AOCNP, discusses the rationale behind a pilot study which will assess patient reported outcomes for patients with lymphoma who develop chemotherapy-induced peripheral lymphoma.
A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.
In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.
The FDA has approved crizotinib as a therapeutic option for patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.
Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
A single-center study evaluated the efficacy of saline flush in pediatric patients with central venous access devices.
Facility characteristics at community-based breast imaging facilities may be linked to screening disparities across ethnic and racial groups.
Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.
Ilene Galinsky, BSN, MSN, ANP-C, discusses the evolution of targeted therapy in acute myeloid leukemia treatment, and how venetoclax plays into the treatment paradigm.
Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.
Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.
Mandible reconstruction and maxilla reconstruction surgeries might be optimized with virtual surgical planning, according to an expert speaker at the 2022 Supportive Care in Cancer Annual Meeting.
